Synthekine

Synthekine

Edit info

  • Founded: 2018
  • Location: Menlo Park, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Immuno-oncology
  • Drug types: ONC, IMM
  • Lead product: STK-012
  • Funding: $100M C Jan 2023; $107.5M B Jun 2021; $82M A Sep 2020
  • Investors: The Column Group


synthekine.com

linkedin.com

job board


Drug notes:

STK-009 2 efforts Clin0/Clin1oncology; undisclosed Clin0 immuno-oncology; 2 undisclosed programs RD/Clin0 autoimmune conditions

About:

Synthekine is developing cytokine therapeutics to develop disease-optimized treatments. Cytokines enable immune cells to communicate and are central to the body’s response to diseases and the maintenance of immune homeostasis. However, cytokines are pleiotropic and can have both efficacious and toxic effects. Synthekine is developing three distinct cytokine engineering platforms that enable them to engineer next-generation cytokine therapeutics biased toward certain receptors. This involves tuning the cytokine receptor binding surface to enhance binding to receptors on efficacy-driving cell types. Synthekine is using their platform to build a pipeline of novel immunotherapies that can deliver cytokine therapeutics for patients with cancer and autoimmune diseases.

Jobs:

Synthekine
SRA II, Analytical Development Biologics
Menlo Park, CA|69 days ago
Apply


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com